Deerfield Management Company L.P. Series C lessened its stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Free Report) by 48.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 930,447 shares of the company’s stock after selling 869,553 shares during […]
Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) and Beam Therapeutics (NASDAQ:BEAM – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends. Insider & Institutional Ownership 80.6% of Beam […]
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 3,350,000 shares, an increase of 12.8% from the October 15th total of 2,970,000 shares. Approximately 9.8% of the shares of the company are short sold. […]
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totalling 2,970,000 shares, an increase of 24.3% from the September 30th total of 2,390,000 shares. Approximately 8.7% of the shares of the company are short sold. […]
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) was the target of a large increase in short interest in September. As of September 15th, there was short interest totalling 1,420,000 shares, an increase of 24.6% from the August 31st total of 1,140,000 shares. Currently, 4.1% of the company’s stock are short sold. Based on […]